CD8A and small cell lung carcinoma: Thus, in this context, we found that there was a greater PFS and OS benefit with both D + EP and D + T + EP versus EP alone in patients with high CD8 cell density compared with in the remaining (CD8-low) population, suggesting CD8 as a marker that may be more specifically aligned with benefit from blockade of the PD-1/PD-L1 axis in ES-SCLC.